Month: March 2025
Sculptra and Hyaluronic Acid Fillers for Facial Rejuvenation in Patients on GLP-1 Inhibitors
The rising use of GLP-1 receptor agonists—such as semaglutide and tirzepatide—for weight loss and diabetes management has led to notable facial volume loss in many patients. This effect, often referred to as ‘Ozempic face,” results from the rapid reduction of subcutaneous fat, leading to skin laxity, hollowness, and increased facial aging. To address these concerns, …